Researchers have developed a new, interpretable artificial intelligence (AI) model to predict 5-year breast cancer risk from mammograms, according to a new study published today in Radiology

Image courtesy of Radiology


April 1, 2024 — Researchers have developed a new, interpretable artificial intelligence (AI) model to predict 5-year breast cancer risk from mammograms, according to a new study published today in Radiology, a journal of the Radiological Society of North America (RSNA).

One in 8 women, or approximately 13% of the female population in the U.S., will develop invasive breast cancer in their lifetime and 1 in 39 women (3%) will die from the disease, according to the American Cancer Society. Breast cancer screening with mammography, for many women, is the best way to find breast cancer early when treatment is most effective. Having regularly scheduled mammograms can significantly lower the risk of dying from breast cancer. However, it remains unclear how to precisely predict which women will develop breast cancer through screening alone.

Mirai, a state-of-the-art, deep learning-based algorithm, has demonstrated proficiency as a tool to help predict breast cancer but, because little is known about its reasoning process, the algorithm has the potential for overreliance by radiologists and incorrect diagnoses.

“Mirai is a black box—a very large and complex neural network, similar in construction to ChatGPT—and no one knew how it made its decisions,” said the study’s lead author, Jon Donnelly, B.S., a Ph.D. student in the Department of Computer Science at Duke University in Durham, North Carolina. “We developed an interpretable AI method that allows us to predict breast cancer from mammograms 1 to 5 years in advance. AsymMirai is much simpler and much easier to understand than Mirai.”

About the Mirai Study

For the study, Donnelly and colleagues in the Department of Computer Science and Department of Radiology compared their newly developed mammography-based deep learning model called AsymMirai to Mirai’s 1- to 5-year breast cancer risk predictions. AsymMirai was built on the “front end” deep learning portion of Mirai, while replacing the rest of that complicated method with an interpretable module: local bilateral dissimilarity, which looks at tissue differences between the left and right breasts.

“Previously, differences between the left and right breast tissue were used only to help detect cancer, not to predict it in advance,” Donnelly said. “We discovered that Mirai uses comparisons between the left and right sides, which is how we were able to design a substantially simpler network that also performs comparisons between the sides.”

For the study, the researchers compared 210,067 mammograms from 81,824 patients in the EMory BrEast imaging Dataset (EMBED) from January 2013 to December 2020 using both Mirai and AsymMirai models. The researchers found that their simplified deep learning model performed almost as well as the state-of-the-art Mirai for 1- to 5-year breast cancer risk prediction.

The results also supported the clinical importance of breast asymmetry and, as a result, highlights the potential of bilateral dissimilarity as a future imaging marker for breast cancer risk.

Since the reasoning behind AsymMirai’s predictions is easy to understand, it could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction, Donnelly said.

“We can, with surprisingly high accuracy, predict whether a woman will develop cancer in the next 1 to 5 years based solely on localized differences between her left and right breast tissue,” he said. “This could have public impact because it could, in the not-too-distant future, affect how often women receive mammograms.”

For more information: www.rsna.org


Related Content

News | X-Ray

July 14, 2026 — A team of crew members aboard a commercial spaceflight acquired the first diagnostic X-rays during an ...

Time July 14, 2026
arrow
News | Ultrasound Imaging

July 7, 2026 — Longeviti Neuro Solutions has launched a new strategic initiative, ClearFit AI, a Brain Ultrasound ...

Time July 09, 2026
arrow
News | Prostate Cancer

July 8,2026 — CorePlus, Puerto Rico’s fully digital precision pathology and clinical laboratory, has announced the ...

Time July 08, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

July 7, 2026 — Imagion Biosystems, Ltd. recently announced it has renewed and extended its collaboration agreement with ...

Time July 07, 2026
arrow
News | Breast Imaging

July 7, 2026 — QT Imaging Holdings, Inc. recently announced it has successfully completed its first routine inspection ...

Time July 07, 2026
arrow
News | MRI Breast

July 2, 2026 – Quibim has announced the European and UK launch of QP-Breast, its CE and UKCA-marked AI tool which ...

Time July 02, 2026
arrow
News | Women's Health

July 1, 2026 — Despite declining birth rates worldwide, the complexity of pregnancy is increasing. Advanced maternal age ...

Time July 01, 2026
arrow
News | Mammography

June 30, 2026 — The Food and Drug Administration has cleared new contrast-enhanced mammography (CEM) and CEM biopsy ...

Time June 30, 2026
arrow
News | Information Technology

June 26, 2026 — Radin Health recently announced the successful deployment of its cloud-native platform at four ...

Time June 26, 2026
arrow
News | FDA

June 25, 2026 — Aidoc recently announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device ...

Time June 25, 2026
arrow
Subscribe Now